1. Patient Travel Concerns After Treatment with 177Lu-DOTATATE
- Author
-
Boris G. Naraev, David J. Mercer, James K. Underwood, Thorvardur R. Halfdanarson, Josh Mailman, and Ayse Tuba Kendi
- Subjects
Oncology ,medicine.medical_specialty ,Advanced Accelerator Applications ,business.industry ,Neuroendocrine tumors ,medicine.disease ,030218 nuclear medicine & medical imaging ,Food and drug administration ,03 medical and health sciences ,0302 clinical medicine ,Somatostatin ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,177Lu-DOTATATE ,Radiology, Nuclear Medicine and imaging ,business ,After treatment - Abstract
Since its approval by the U.S. Food and Drug Administration in late January 2018, 177Lu-labeled DOTATATE (Lutathera; Advanced Accelerator Applications, a Novartis company) has been used for the treatment of advanced somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors by
- Published
- 2020